Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · 4

Biodesix, Inc.

BDSXNASDAQEQUITYCurrent

SEC Filing

Filed Aug 13, 2026Accepted Aug 13, 2026, 5:22 PM EDTCIK 1439725Accession 0000905148-26-003641
Share

Company context

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, including the Nodify Lung® Nodule Risk Assessment test and the IQLung® Cancer Treatment Guidance test, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Current securities

Recent company filings

  1. 4 filingAug 12, 2026
  2. 10-Q filingAug 5, 2026
  3. Results of Operations and Financial ConditionAug 5, 2026
  4. SCHEDULE 13G - filed by Soleus Capital Master Fund, L.P. regarding BIODESIX INCJun 18, 2026
  5. 424B3 filingJun 1, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗